$2.07
Brainstorm Cell Therapeutics is a biotechnology business based in the US. Brainstorm Cell Therapeutics shares (BCLI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.19 – an increase of 3.3% over the previous week. Brainstorm Cell Therapeutics employs 29 staff and has a market cap (total outstanding shares value) of 0.00.
What's in this guide?
- BCLI shares summary
- Compare share dealing platforms
- Is BCLI stock a buy or sell?
- Stock performance over time
- Can I short BCLI shares?
- Brainstorm Cell Therapeutics's financials
- How volatile are BCLI shares?
- Does Brainstorm Cell Therapeutics pay a dividend?
- Have BCLI shares ever split?
- Other common questions
Our top picks for where to buy Brainstorm Cell Therapeutics stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Brainstorm Cell Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BCLI. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Brainstorm Cell Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Brainstorm Cell Therapeutics stock price (NASDAQ: BCLI)
Use our graph to track the performance of BCLI stocks over time.Brainstorm Cell Therapeutics shares at a glance
Latest market close | $2.19 |
---|---|
52-week range | $1.96 - $11.89 |
50-day moving average | $3.86 |
200-day moving average | $5.70 |
Wall St. target price | $29.50 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-3.30 |
Is it a good time to buy Brainstorm Cell Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Brainstorm Cell Therapeutics price performance over time
Historical closes compared with the close of $2.25 from 2024-10-18
1 week (2024-10-15) | 6.13% |
---|---|
1 month (2024-09-20) | 826.69% |
3 months (2024-07-22) | 526.74% |
6 months (2024-04-22) | 316.59% |
1 year (2023-10-20) | 1,164.04% |
---|---|
2 years (2022-10-21) | -29.25% |
3 years (2021-10-22) | 3.08 |
5 years (2019-10-22) | 3.9 |
Brainstorm Cell Therapeutics financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -178.2% |
Return on equity TTM | -1121.9% |
Profit margin | 0% |
Book value | $-0.66 |
Market Capitalization | $11.3 million |
TTM: trailing 12 months
Brainstorm Cell Therapeutics share dividends
We're not expecting Brainstorm Cell Therapeutics to pay a dividend over the next 12 months.
Have Brainstorm Cell Therapeutics's shares ever split?
Brainstorm Cell Therapeutics's shares were split on a 1:15 basis on 30 September 2024 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Brainstorm Cell Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Brainstorm Cell Therapeutics shares which in turn could have impacted Brainstorm Cell Therapeutics's share price.
Brainstorm Cell Therapeutics share price volatility
Over the last 12 months, Brainstorm Cell Therapeutics's shares have ranged in value from as little as $1.9578 up to $11.8905. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Brainstorm Cell Therapeutics's is 0.323. This would suggest that Brainstorm Cell Therapeutics's shares are less volatile than average (for this exchange).
Brainstorm Cell Therapeutics overview
Brainstorm Cell Therapeutics Inc. , a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. .
Frequently asked questions
nullWhat percentage of Brainstorm Cell Therapeutics is owned by insiders or institutions?
Currently 9.04% of Brainstorm Cell Therapeutics shares are held by insiders and 15.36% by institutions. How many people work for Brainstorm Cell Therapeutics?
Latest data suggests 29 work at Brainstorm Cell Therapeutics. When does the fiscal year end for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics's fiscal year ends in December. Where is Brainstorm Cell Therapeutics based?
Brainstorm Cell Therapeutics's address is: 1325 Avenue of Americas, New York, NY, United States, 10019 What is Brainstorm Cell Therapeutics's ISIN number?
Brainstorm Cell Therapeutics's international securities identification number is: US10501E2019 What is Brainstorm Cell Therapeutics's CUSIP number?
Brainstorm Cell Therapeutics's Committee on Uniform Securities Identification Procedures number is: 10501E102
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
eToro review 2024: Commission-free social trading and investing
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
-
Titan Review 2024: Wealth Management With a No-Advisory-Fee Robo-Advisor
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
-
Public.com Review 2024: No-Fee Options, With Rebates
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question